antibiotics

Biopharma has abandoned antibiotic development. Here’s why we did, too.
Biopharma has abandoned antibiotic development. Here’s why we did, too.
Endpoints
Octagon Therapeutics
drug discovery
drug development
antibiotics
Flag link:
With looming superbug crisis, Iterum misses in a key antibiotic trial — and its shares tumble
With looming superbug crisis, Iterum misses in a key antibiotic trial — and its shares tumble
Endpoints
Iterum
sulopenem
antibiotics
clinical trial
antibiotic resistance
Flag link:
Brii bags rights to tuberculosis drug to further antibiotic push
Brii bags rights to tuberculosis drug to further antibiotic push
Fierce Biotech
Brii Biosciences
China
AN2 Therapeutics
tuberculosis
antibiotics
Flag link:
FDA Approves Talicia To Treat Superbug Linked To Stomach Cancer
FDA Approves Talicia To Treat Superbug Linked To Stomach Cancer
Forbes
superbugs
antibiotics
antibiotic resistance
Talicia
FDA
stomach bug
Helicobecter pylori
Redhill Biopharma
Flag link:
After positive panel vote, Shionogi antibiotic scores US approval
After positive panel vote, Shionogi antibiotic scores US approval
Endpoints
Shionogi
antibiotics
FDA
cUTI
UTIs
Fetroja
Flag link:
CDC report: 35,000 Americans die of antibiotic-resistant infections each year
CDC report: 35,000 Americans die of antibiotic-resistant infections each year
Stat
CDC
antibiotics
antibiotic resistance
Flag link:
As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval
As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval
Endpoints
WHO
H pylori
Redhill Biopharma
antibiotics
antibiotic resistance
rifabutin
FDA
Flag link:
Why Scott Gottlieb, venture capitalist, sees opportunity in antibiotics
Why Scott Gottlieb, venture capitalist, sees opportunity in antibiotics
Endpoints
Scott Gottlieb
FDA
antibiotics
drug development
Flag link:
GlaxoSmithKline kick-starts first-of-its-kind late-stage antibiotic test
GlaxoSmithKline kick-starts first-of-its-kind late-stage antibiotic test
Fierce Biotech
GSK
antibiotics
antibiotic resistance
gepotidacin
Flag link:
Researchers Estimate Costs of Exclusivity Extensions to Encourage Antibiotic Development
Researchers Estimate Costs of Exclusivity Extensions to Encourage Antibiotic Development
RAPS.org
legistlation
regulatory
exclusivity
antibiotics
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
Still too little progress on antibiotic resistance, says O’Neill report update
Still too little progress on antibiotic resistance, says O’Neill report update
Pharmaforum
antibiotics
antibiotic resistance
drug development
Flag link:
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Endpoints
Shionogi
antibiotics
FDA
cefiderocol
nosocomial pneumonia
Flag link:
MGB tops up cash pool to wrap up antibiotic phase 2a
MGB tops up cash pool to wrap up antibiotic phase 2a
Fierce Biotech
MGB Biopharma
antibiotics
MGB-BP-3
C. difficile
clinical trials
Flag link:
Nabriva gets first approval in novel antibiotic class
Nabriva gets first approval in novel antibiotic class
BioCentury
Nabriva
antibiotics
Xenleta
lefamulin
community-acquired bacterial pneumonia
Flag link:
Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another
BioCentury
Nabriva Therapeutics
antibiotics
lefmulin
Flag link:
CMS prescribes payment fix to resuscitate US antibiotic industry
CMS prescribes payment fix to resuscitate US antibiotic industry
Endpoints
CMS
antibiotics
drug development
Flag link:
Why Merck is in infectious disease for the long haul
Why Merck is in infectious disease for the long haul
BioCentury
Merck
R&D
infectious diseases
antibiotics
Flag link:
U.K. launches subscription model to pay for antibiotics
U.K. launches subscription model to pay for antibiotics
BioCentury
UK
antibiotics
subscription model
Flag link:

Pages